CN110545844A - 使用结合细胞毒性t淋巴细胞抗原-4(ctla-4)的抗体的癌症治疗 - Google Patents

使用结合细胞毒性t淋巴细胞抗原-4(ctla-4)的抗体的癌症治疗 Download PDF

Info

Publication number
CN110545844A
CN110545844A CN201880026480.5A CN201880026480A CN110545844A CN 110545844 A CN110545844 A CN 110545844A CN 201880026480 A CN201880026480 A CN 201880026480A CN 110545844 A CN110545844 A CN 110545844A
Authority
CN
China
Prior art keywords
sequence
seq
antibody
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880026480.5A
Other languages
English (en)
Chinese (zh)
Inventor
弗兰克·J·卡尔佐内
严海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rui Virtues Bio Medicine Technology Co Ltd
Original Assignee
Rui Virtues Bio Medicine Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rui Virtues Bio Medicine Technology Co Ltd filed Critical Rui Virtues Bio Medicine Technology Co Ltd
Publication of CN110545844A publication Critical patent/CN110545844A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880026480.5A 2017-02-21 2018-01-05 使用结合细胞毒性t淋巴细胞抗原-4(ctla-4)的抗体的癌症治疗 Pending CN110545844A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762461560P 2017-02-21 2017-02-21
US62/461,560 2017-02-21
PCT/US2018/012545 WO2018156250A1 (en) 2017-02-21 2018-01-05 Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4)

Publications (1)

Publication Number Publication Date
CN110545844A true CN110545844A (zh) 2019-12-06

Family

ID=63254023

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880026480.5A Pending CN110545844A (zh) 2017-02-21 2018-01-05 使用结合细胞毒性t淋巴细胞抗原-4(ctla-4)的抗体的癌症治疗

Country Status (5)

Country Link
US (1) US11319372B2 (https=)
EP (1) EP3585430A4 (https=)
JP (1) JP7165995B2 (https=)
CN (1) CN110545844A (https=)
WO (1) WO2018156250A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113244389A (zh) * 2021-07-06 2021-08-13 诺赛联合(北京)生物医学科技有限公司 一种TILs细胞制备方法及在肿瘤治疗的用途
WO2023134771A1 (zh) * 2022-01-17 2023-07-20 上海君实生物医药科技股份有限公司 抗ctla-4抗体药物组合物及其用途
WO2025140296A1 (zh) * 2023-12-26 2025-07-03 上海宏成药业有限公司 抗dll3抗体或其抗原结合片段及其用途

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
MX2018013386A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
DK3551660T5 (da) 2016-12-07 2024-09-02 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
JP7173993B2 (ja) 2017-05-19 2022-11-17 ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210108978A (ko) 2018-12-21 2021-09-03 오제 이뮈노테라프틱스 이작용성 항-pd-1/il-7 분자
CA3122773A1 (en) 2018-12-26 2020-07-02 Xilio Development, Inc. Anti-ctla4 antibodies and methods of use thereof
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
WO2020163817A1 (en) * 2019-02-08 2020-08-13 Prothena Biosciences Limited Antibodies recognizing tau
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
JP7630834B2 (ja) 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
WO2021170750A1 (en) 2020-02-28 2021-09-02 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2021250594A1 (en) 2020-06-11 2021-12-16 Nantbio, Inc. Anti-ctla4 monoclonal antibodies and chimeric antigen receptors
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
JP2025525886A (ja) 2022-08-02 2025-08-07 オーエスイー・イミュノセラピューティクス Ｃｄ２８に対する多機能性分子
EP4687991A1 (en) 2023-03-30 2026-02-11 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026012032A1 (en) * 2024-07-10 2026-01-15 Wuxi Biologics (Shanghai) Co., Ltd. Antibodies against integrin and uses thereof
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037504A2 (en) * 1998-12-23 2000-06-29 Pfizer Inc. Human monoclonal antibodies to ctla-4
US20050277173A1 (en) * 2004-06-14 2005-12-15 Li-Te Chin Method for producing human antibodies with properties of agonist, antagonist, or inverse agonist
WO2012120125A1 (en) * 2011-03-09 2012-09-13 Antitope Ltd Humanised anti ctla-4 antibodies
US20130022616A1 (en) * 2011-07-21 2013-01-24 Pfizer Inc. Interleukin-31 Monoclonal Antibody
CN104292334A (zh) * 2014-04-25 2015-01-21 河南省健康伟业生物医药研究股份有限公司 一种全人源抗ctla-4单克隆抗体、制备方法及应用
US20160237154A1 (en) * 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
WO2016196237A1 (en) * 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2749571A3 (en) 2006-01-10 2014-08-13 ZymoGenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31RA and OSMRb antagonists
WO2009100140A1 (en) 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
CN101628940B (zh) * 2008-07-15 2011-11-23 中国科学院生物物理研究所 一种单克隆抗体及其应用
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037504A2 (en) * 1998-12-23 2000-06-29 Pfizer Inc. Human monoclonal antibodies to ctla-4
US20050277173A1 (en) * 2004-06-14 2005-12-15 Li-Te Chin Method for producing human antibodies with properties of agonist, antagonist, or inverse agonist
WO2012120125A1 (en) * 2011-03-09 2012-09-13 Antitope Ltd Humanised anti ctla-4 antibodies
US20130022616A1 (en) * 2011-07-21 2013-01-24 Pfizer Inc. Interleukin-31 Monoclonal Antibody
CN104292334A (zh) * 2014-04-25 2015-01-21 河南省健康伟业生物医药研究股份有限公司 一种全人源抗ctla-4单克隆抗体、制备方法及应用
US20160237154A1 (en) * 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
WO2016196237A1 (en) * 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VALENTINA CECCHINATO 等: "Immune activation drived by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection", 《J IMMUNOL》 *
卢洋 等: "人CTLA4单克隆抗体的制备和鉴定", 《医学研究生学报》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113244389A (zh) * 2021-07-06 2021-08-13 诺赛联合(北京)生物医学科技有限公司 一种TILs细胞制备方法及在肿瘤治疗的用途
WO2023134771A1 (zh) * 2022-01-17 2023-07-20 上海君实生物医药科技股份有限公司 抗ctla-4抗体药物组合物及其用途
WO2025140296A1 (zh) * 2023-12-26 2025-07-03 上海宏成药业有限公司 抗dll3抗体或其抗原结合片段及其用途

Also Published As

Publication number Publication date
EP3585430A4 (en) 2020-12-09
EP3585430A1 (en) 2020-01-01
JP2020508655A (ja) 2020-03-26
WO2018156250A1 (en) 2018-08-30
JP7165995B2 (ja) 2022-11-07
US11319372B2 (en) 2022-05-03
US20200055937A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
CN110545844A (zh) 使用结合细胞毒性t淋巴细胞抗原-4(ctla-4)的抗体的癌症治疗
RU2766582C2 (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP6506280B2 (ja) 抗ｃｘｃｒ４抗体および抗体−薬剤コンジュゲート
EP4281484B1 (en) Anti-her-2/trop-2 constructs and uses thereof
US11242398B2 (en) Anti-OX40 antibodies and methods of activating OX40
CN110366564B (zh) 使用与程序性死亡1(pd-1)结合的抗体的免疫疗法
US20260109770A1 (en) C-c chemokine receptor type 8 (ccr8) antagonist antibodies
WO2021216832A1 (en) Chemokine receptor 4 (cxcr4) antagonist antibodies
CN115803062B (zh) 滋养层细胞表面抗原2(trop-2)抗体
US12617857B2 (en) Chemokine receptor 4 (CXCR4) antagonist antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191206